These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

131 related items for PubMed ID: 22054762

  • 1. Biologics and infections: lessons from tumor necrosis factor blocking agents.
    Wallis RS.
    Infect Dis Clin North Am; 2011 Dec; 25(4):895-910. PubMed ID: 22054762
    [Abstract] [Full Text] [Related]

  • 2. Infections during treatment with biological agents and possible treatment in clinical practice.
    Atzeni F, Benucci M, Sarzi-Puttini P.
    Expert Rev Clin Immunol; 2013 Mar; 9(3):193-5. PubMed ID: 23445193
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. [Infectious risk].
    Calabuig E, Salavert M.
    Actas Dermosifiliogr; 2008 Jul; 99 Suppl 4():14-22. PubMed ID: 19080987
    [Abstract] [Full Text] [Related]

  • 5. Update upon efficacy and safety of TNF-α inhibitors.
    Murdaca G, Colombo BM, Cagnati P, Gulli R, Spanò F, Puppo F.
    Expert Opin Drug Saf; 2012 Jan; 11(1):1-5. PubMed ID: 22010813
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Tuberculosis associated with blocking agents against tumor necrosis factor-alpha--California, 2002-2003.
    Centers for Disease Control and Prevention (CDC).
    MMWR Morb Mortal Wkly Rep; 2004 Aug 06; 53(30):683-6. PubMed ID: 15295313
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Tuberculosis and Legionella pneumophila pneumonia in a patient receiving anti-tumour necrosis factor-alpha (anti-TNF-alpha) treatment.
    Mancini G, Erario L, Gianfreda R, Oliva A, Massetti AP, Mastroianni CM, Vullo V.
    Clin Microbiol Infect; 2007 Oct 06; 13(10):1036-7. PubMed ID: 17711485
    [No Abstract] [Full Text] [Related]

  • 14. Tumor necrosis factor antagonists: preliminary evidence for an emerging approach in the treatment of ocular inflammation.
    Theodossiadis PG, Markomichelakis NN, Sfikakis PP.
    Retina; 2007 Oct 06; 27(4):399-413. PubMed ID: 17420690
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. [Protocol for inducing infliximab tolerance in a patient with psoriatic spondylarthritis].
    Gallardo R, Fobelo MJ, Pastor C, Orta-Cuevas JC.
    Farm Hosp; 2010 Oct 06; 34(2):94-6. PubMed ID: 20304368
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. The safety of anti-tumour necrosis factor therapy in rheumatoid arthritis.
    Askling J, Dixon W.
    Curr Opin Rheumatol; 2008 Mar 06; 20(2):138-44. PubMed ID: 18349742
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.